Table Adverse events with administration of the Ad26.COV2.S vaccine versus placebo, stratified by age of clinical trial participants

Adverse events within 7 days of administration; study participants aged 18-59 years

Adverse event reported

Percentage (%)

Local erythema

9.0

Local swelling

7.0

Pain at injection site

58.6

Fatigue

43.8

Headache

44.4

Nausea

15.5

Fever

12.8

Myalgia

39.1

Adverse events within 7 days of administration; study participants aged ≥60 years

Adverse event reported

Percentage (%)

Local erythema

4.6

Local swelling

2.7

Pain at injection site

33.3

Fatigue

29.7

Headache

30.4

Nausea

12.3

Fever

3.1

Myalgia

24.0

Adapted from Product Monograph including Patient Medication Information: Janssen COVID-19 Vaccine: SARS-CoV-2 Vaccine (Ad26.COV2.S, recombinant).